Skip to main content
PMC home page
The Yale Journal of Biology and Medicine logoLink to The Yale Journal of Biology and Medicine
. 1998 Mar-Apr;71(2):119–124.

Treatment of H. pylori infection: the reality.

N Vakil 1
PMCID: PMC2578890  PMID: 10378357

Abstract

Despite the wide dissemination of information on Helicobacter pylori, there is still a great deal of variation in how general practitioners treat the infection and in which circumstances they prescribe eradication therapy for H. pylori. Specialty societies have developed consensus guidelines that recommend a strategy to test and treat dyspeptic patients for H. pylori infection although the data to support these recommendations are weak at the present time. As a result, there is still confusion about the indications for treatment and the treatment regimens that are likely to be effective in routine clinical practice.

Full text

PDF
119

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bell G. D., Powell K., Burridge S. M., Pallecaros A., Jones P. H., Gant P. W., Harrison G., Trowell J. E. Experience with 'triple' anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther. 1992 Aug;6(4):427–435. doi: 10.1111/j.1365-2036.1992.tb00556.x. [DOI] [PubMed] [Google Scholar]
  2. Bytzer P., Hansen J. M., Schaffalitzky de Muckadell O. B. Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet. 1994 Apr 2;343(8901):811–816. doi: 10.1016/s0140-6736(94)92023-0. [DOI] [PubMed] [Google Scholar]
  3. Cutler A. F., Schubert T. T. Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol. 1993 Apr;88(4):505–509. [PubMed] [Google Scholar]
  4. Graham D. Y., Lew G. M., Malaty H. M., Evans D. G., Evans D. J., Jr, Klein P. D., Alpert L. C., Genta R. M. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 1992 Feb;102(2):493–496. doi: 10.1016/0016-5085(92)90095-g. [DOI] [PubMed] [Google Scholar]
  5. Johnsen R., Bernersen B., Straume B., Førde O. H., Bostad L., Burhol P. G. Prevalences of endoscopic and histological findings in subjects with and without dyspepsia. BMJ. 1991 Mar 30;302(6779):749–752. doi: 10.1136/bmj.302.6779.749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Lind T., Veldhuyzen van Zanten S., Unge P., Spiller R., Bayerdörffer E., O'Morain C., Bardhan K. D., Bradette M., Chiba N., Wrangstadh M. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter. 1996 Sep;1(3):138–144. doi: 10.1111/j.1523-5378.1996.tb00027.x. [DOI] [PubMed] [Google Scholar]
  7. Logan R. P., Bardhan K. D., Celestin L. R., Theodossi A., Palmer K. R., Reed P. I., Baron J. H., Misiewicz J. J. Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: a randomized, double-blind, multi-centre trial of omeprazole with or without clarithromycin. Aliment Pharmacol Ther. 1995 Aug;9(4):417–423. doi: 10.1111/j.1365-2036.1995.tb00400.x. [DOI] [PubMed] [Google Scholar]
  8. McNulty C. A., Dent J. C. Susceptibility of clinical isolates of Campylobacter pylori to twenty-one antimicrobial agents. Eur J Clin Microbiol Infect Dis. 1988 Aug;7(4):566–569. doi: 10.1007/BF01962617. [DOI] [PubMed] [Google Scholar]
  10. Parsonnet J., Harris R. A., Hack H. M., Owens D. K. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet. 1996 Jul 20;348(9021):150–154. doi: 10.1016/s0140-6736(96)01501-2. [DOI] [PubMed] [Google Scholar]
  11. Penston J. G., Mistry K. R. Eradication of Helicobacter pylori in general practice. Aliment Pharmacol Ther. 1996 Apr;10(2):139–145. doi: 10.1046/j.1365-2036.1996.745128000.x. [DOI] [PubMed] [Google Scholar]
  12. Roll J., Weng A., Newman J. Diagnosis and treatment of Helicobacter pylori infection among California Medicare patients. Arch Intern Med. 1997 May 12;157(9):994–998. [PubMed] [Google Scholar]
  13. Schwartz L. M., Woloshin S., Welch H. G. Trends in diagnostic testing following a national guideline for evaluation of dyspepsia. Arch Intern Med. 1996 Apr 22;156(8):873–875. [PubMed] [Google Scholar]
  14. Talley N. J. A critique of therapeutic trials in Helicobacter pylori-positive functional dyspepsia. Gastroenterology. 1994 May;106(5):1174–1183. doi: 10.1016/0016-5085(94)90007-8. [DOI] [PubMed] [Google Scholar]
  15. The British Society of Gastroenterology spring meeting 20-22 March 1996. Abstracts. Gut. 1996;38 (Suppl 1):A1–73. [PMC free article] [PubMed] [Google Scholar]
  16. Vakil N., Fennerty M. B. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer. Am J Gastroenterol. 1996 Feb;91(2):239–245. [PubMed] [Google Scholar]

Articles from The Yale Journal of Biology and Medicine are provided here courtesy of Yale Journal of Biology and Medicine

RESOURCES